Program at a Glance

To view the Program at a Glance, please select the destination below that is closest to your time zone and you will be redirected to a downloadable PDF.

San Francisco Denver New York Rome Singapore Sydney IASLC Meeting Site

Detailed Program

Day 1

Friday, October 29, 2021

Day 2

Saturday, October 30, 2021

1635519600

1635548700

IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer - Day 1

Friday, October 29
11:00 - 19:05 ET | 15:00 - 23:05 UTC | Local Time

104

Opening Ceremony and Keynote

Presentations: 6 | 11:00 - 12:10 ET | 15:00 - 16:10 UTC
- 122
  
  Chairs' Welcome Address
  
  11:00 - 11:05
  Speaker(s)
  
  Charlie Rudin
  USA
  
  Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
- 123
  
  IASLC President Welcome
  
  11:05 - 11:08
  Speaker(s)
  
  Heather Wakelee
  USA
  
  Dr. Heather Wakelee is the Chief and Professor of Medicine in the Division of Oncology at Stanford University. She is also the Deputy Director of the Stanford Cancer Institute. Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. She is also involved in trials of adjuvant therapy, immunotherapy and anti-angiogenesis agents in addition to collaborations with colleagues focused in biomarkers and others focused in population science research. Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as the President-elect for the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO).
- 124
  
  IASLC Membership: Why We Should All Be IASLC Members
  
  11:08 - 11:10
  Speaker(s)
  
  Katie Maher
  USA
  
  Katie Maher joins the IASLC as its Member Experience Coordinator. A graduate of Colorado State University in Business Administration, Katie has a wide array of diverse experience in marketing, content creation, customer service and event planning. And as part of the Member Experience team, Katie will provide incredible support to our members, meeting attendees, partners and other stakeholders.
- 125
  
  Remembrance for Pierre Massion
  
  11:10 - 11:13
  Speaker(s)
  
  Johathan Lehman
  USA
  
  Dr. Jonathan Lehman is a practicing medical thoracic oncologist at Vanderbilt University Medical Center and the Department of Veterans Affairs in Nashville, TN. Dr. Lehman’s current research focuses on small cell lung carcinoma (SCLC), the most aggressive subtype of lung cancer, and is driven by his clinical experience with his patients and Veterans who are disproportionately afflicted by the disease. SCLC is particularly devastating because most tumors develop metastatic recurrence despite initial response to therapeutic intervention. Dr. Lehman’s research focuses on rare chemotherapy resistant subpopulations and he has described distinct neuroendocrine survival signaling in SCLC and rare chemotherapy stable subpopulations uncovered by a novel single cell mass cytometry panel that can identify the expression of more than 40 individual proteins to cluster subpopulations of cells within a large number of tumor cells. He is delighted to participate in the Vanderbilt University U54 group focused on characterizing and modeling different subpopulations in Small Cell Lung Cancer. He is grateful to the NCI, VA, and Department of Defense for continued funding support and his collaborators in the Rudin, ECOG and U54 labs. He is grateful for the support of his former research mentor Dr. Pierre Massion, who is dearly missed.
- 126
  
  Keynote: Lessons from SCLC CDX Models
  
  11:13 - 11:42
  Speaker(s)
  
  Caroline Dive
  United Kingdom
  
  Upon completing her PhD studies in Cambridge, Professor Caroline Dive moved to Aston University's School of Pharmaceutical Sciences in Birmingham where she established her own group studying mechanisms of drug induced tumour cell death, before moving to The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before joining the Cancer Research UK Manchester Institute (CRUK MI) in 2003. Currently, she is Interim Director of the Institute and Director of its Cancer Biomarker Centre, with research spanning tumour biology, biomarker discovery and preclinical pharmacology alongside regulated laboratories for biomarker assay validation and qualification within clinical trials to Good Clinical Practice standards supporting clinical decision-making. Caroline was awarded the Pasteur-Weizmann/Servier International Prize in 2012 for her Biomarker Research, the AstraZeneca Prize for Women in Pharmacology in 2016 and was presented with the 2019 Heine H. Hansen Lectureship Award by the International Association for the Study of Lung Cancer (IASLC). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research. Most recently, she became an elected member of EMBO (2020), received the inaugural Johann Anton Merck Award in recognition for exceptional contributions to the field of preclinical oncology (2020) and was the recipient of the Mary J. Matthews Pathology/Translational Distinguished Service Award by IASLC (2021). Caroline is the current President of the European Association for Cancer Research (2020 – 2022).
- 127
  
  Keynote Discussion with Q+A
  
  11:42 - 12:10
  Speaker(s)
  
  Caroline Dive
  United Kingdom
  
  Upon completing her PhD studies in Cambridge, Professor Caroline Dive moved to Aston University's School of Pharmaceutical Sciences in Birmingham where she established her own group studying mechanisms of drug induced tumour cell death, before moving to The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before joining the Cancer Research UK Manchester Institute (CRUK MI) in 2003. Currently, she is Interim Director of the Institute and Director of its Cancer Biomarker Centre, with research spanning tumour biology, biomarker discovery and preclinical pharmacology alongside regulated laboratories for biomarker assay validation and qualification within clinical trials to Good Clinical Practice standards supporting clinical decision-making. Caroline was awarded the Pasteur-Weizmann/Servier International Prize in 2012 for her Biomarker Research, the AstraZeneca Prize for Women in Pharmacology in 2016 and was presented with the 2019 Heine H. Hansen Lectureship Award by the International Association for the Study of Lung Cancer (IASLC). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research. Most recently, she became an elected member of EMBO (2020), received the inaugural Johann Anton Merck Award in recognition for exceptional contributions to the field of preclinical oncology (2020) and was the recipient of the Mary J. Matthews Pathology/Translational Distinguished Service Award by IASLC (2021). Caroline is the current President of the European Association for Cancer Research (2020 – 2022).
  
  Charlie Rudin
  USA
  
  Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
105

Single Cell Analysis in SCLC

Presentations: 5 | 12:10 - 13:20 ET | 16:10 - 17:20 UTC
- 128
  
  Signatures of Plasticity, Metastasis and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer
  
  12:10 - 12:22
  Speaker(s)
  
  Joseph Chan
  USA
  
  Dr. Chan completed his MD/PhD at Columbia University College of Physicians and Surgeons, where he studied computational biology and developed new methods to model the topology of viral evolution and identify recurrent FGFR-TACC fusions in glioblastoma multiforme. He is currently an Instructor in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center where he aims to leverage single-cell technologies and machine learning to understand how neuroendocrine lineage plasticity in lung and prostate cancer mediates metastasis and therapeutic resistance, and how the tumor microenvironment can fuel this tumor-intrinsic process.
- 129
  
  Plasticity of SCLC Subtypes: Lessons from GEMMs
  
  12:22 - 12:24
  Speaker(s)
  
  Trudy Oliver
  USA
  
  Dr. Oliver received her PhD from Duke University in 2005 in Pharmacology and Cancer Biology as a graduate student in Dr. Rob Wechsler-Reya's lab. She completed a Postdoctoral Fellowship (2006-2011) in Dr. Tyler Jack's lab at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT), Boston, MA. Dr. Oliver joined the University of Utah and Huntsman Cancer Institute in 2011. She is now Associate Professor with tenure and a Huntsman Cancer Institute (HCI) Endowed Chair in Cancer Research in the Department of Oncological Sciences. Dr. Oliver is a co-leader of the Cell Response and Regulation (CRR) and co-leader of the Lung Cancer Disease Center at HCI. Dr. Oliver has received many awards including a National Science Foundation (NSF) graduate student fellowship, and two postdoctoral fellowships from ASPET-Merck and the Ludwig Foundation at MIT. As an independent investigator, she has received awards from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, American Cancer Society, American Lung Association, and was honored with a William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation (LCRF). Research: Dr. Oliver's research is devoted to understanding mechanisms of lung cancer biology with the goal of identifying novel therapeutic targets to improve patient outcome. As a graduate student at Duke, she studied the developmental origins of the childhood brain tumor, medulloblastoma, where she identified mechanisms of tumor progression in mouse models of the disease. As a postdoctoral fellow at MIT and as an independent investigator, she has developed novel mouse models of squamous and small cell lung cancer. Her work has contributed to our understanding of the Mdm2/p53 pathway, chemotherapy resistance mechanisms, and the functions of oncogenic transcription factors like Sox2, Nkx2-1, and Myc. Dr. Oliver’s laboratory integrates mouse genetics, molecular and cellular biology, biochemistry, single cell genomics, in vivo imaging, and preclinical therapeutics. Teaching and Mentoring: Dr. Oliver has been active in graduate student and medical school teaching. Dr. Oliver's trainees have received a number of prestigious awards. These include the Susan Cooper Jones Postdoc of the Year Award, the James W. Prahl Memorial Graduate Student of the Year award, an NIH NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. In addition, Oliver lab trainees have won a number of travel awards including to Keystone Symposia and selection as a recipient to the 68th Annual Lindau Nobel Laureate meeting in Germany.
- 130
  
  Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity
  
  12:24 - 12:36
  Speaker(s)
  
  Lauren Byers
  USA
  
  Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas. She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences. She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group. Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards, the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award, and most recently, membership of The American Society for Clinical Investigation (ASCI). As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC. Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models. Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models (published in Cancer Cell 2021 and Nature Cancer 2020).
- 131
  
  Single Cell Mass Cytometry and SCLC Models
  
  12:36 - 12:48
  Speaker(s)
  
  Johathan Lehman
  USA
  
  Dr. Jonathan Lehman is a practicing medical thoracic oncologist at Vanderbilt University Medical Center and the Department of Veterans Affairs in Nashville, TN. Dr. Lehman’s current research focuses on small cell lung carcinoma (SCLC), the most aggressive subtype of lung cancer, and is driven by his clinical experience with his patients and Veterans who are disproportionately afflicted by the disease. SCLC is particularly devastating because most tumors develop metastatic recurrence despite initial response to therapeutic intervention. Dr. Lehman’s research focuses on rare chemotherapy resistant subpopulations and he has described distinct neuroendocrine survival signaling in SCLC and rare chemotherapy stable subpopulations uncovered by a novel single cell mass cytometry panel that can identify the expression of more than 40 individual proteins to cluster subpopulations of cells within a large number of tumor cells. He is delighted to participate in the Vanderbilt University U54 group focused on characterizing and modeling different subpopulations in Small Cell Lung Cancer. He is grateful to the NCI, VA, and Department of Defense for continued funding support and his collaborators in the Rudin, ECOG and U54 labs. He is grateful for the support of his former research mentor Dr. Pierre Massion, who is dearly missed.
- 132
  
  Panel Discussion with Q&A
  
  12:48 - 13:20
  Speaker(s)
  
  Lauren Byers
  USA
  
  Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas. She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences. She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group. Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards, the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award, and most recently, membership of The American Society for Clinical Investigation (ASCI). As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC. Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models. Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models (published in Cancer Cell 2021 and Nature Cancer 2020).
  
  Joseph Chan
  USA
  
  Dr. Chan completed his MD/PhD at Columbia University College of Physicians and Surgeons, where he studied computational biology and developed new methods to model the topology of viral evolution and identify recurrent FGFR-TACC fusions in glioblastoma multiforme. He is currently an Instructor in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center where he aims to leverage single-cell technologies and machine learning to understand how neuroendocrine lineage plasticity in lung and prostate cancer mediates metastasis and therapeutic resistance, and how the tumor microenvironment can fuel this tumor-intrinsic process.
  
  Caroline Dive
  United Kingdom
  
  Upon completing her PhD studies in Cambridge, Professor Caroline Dive moved to Aston University's School of Pharmaceutical Sciences in Birmingham where she established her own group studying mechanisms of drug induced tumour cell death, before moving to The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before joining the Cancer Research UK Manchester Institute (CRUK MI) in 2003. Currently, she is Interim Director of the Institute and Director of its Cancer Biomarker Centre, with research spanning tumour biology, biomarker discovery and preclinical pharmacology alongside regulated laboratories for biomarker assay validation and qualification within clinical trials to Good Clinical Practice standards supporting clinical decision-making. Caroline was awarded the Pasteur-Weizmann/Servier International Prize in 2012 for her Biomarker Research, the AstraZeneca Prize for Women in Pharmacology in 2016 and was presented with the 2019 Heine H. Hansen Lectureship Award by the International Association for the Study of Lung Cancer (IASLC). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research. Most recently, she became an elected member of EMBO (2020), received the inaugural Johann Anton Merck Award in recognition for exceptional contributions to the field of preclinical oncology (2020) and was the recipient of the Mary J. Matthews Pathology/Translational Distinguished Service Award by IASLC (2021). Caroline is the current President of the European Association for Cancer Research (2020 – 2022).
  
  Johathan Lehman
  USA
  
  Dr. Jonathan Lehman is a practicing medical thoracic oncologist at Vanderbilt University Medical Center and the Department of Veterans Affairs in Nashville, TN. Dr. Lehman’s current research focuses on small cell lung carcinoma (SCLC), the most aggressive subtype of lung cancer, and is driven by his clinical experience with his patients and Veterans who are disproportionately afflicted by the disease. SCLC is particularly devastating because most tumors develop metastatic recurrence despite initial response to therapeutic intervention. Dr. Lehman’s research focuses on rare chemotherapy resistant subpopulations and he has described distinct neuroendocrine survival signaling in SCLC and rare chemotherapy stable subpopulations uncovered by a novel single cell mass cytometry panel that can identify the expression of more than 40 individual proteins to cluster subpopulations of cells within a large number of tumor cells. He is delighted to participate in the Vanderbilt University U54 group focused on characterizing and modeling different subpopulations in Small Cell Lung Cancer. He is grateful to the NCI, VA, and Department of Defense for continued funding support and his collaborators in the Rudin, ECOG and U54 labs. He is grateful for the support of his former research mentor Dr. Pierre Massion, who is dearly missed.
  
  Trudy Oliver
  USA
  
  Dr. Oliver received her PhD from Duke University in 2005 in Pharmacology and Cancer Biology as a graduate student in Dr. Rob Wechsler-Reya's lab. She completed a Postdoctoral Fellowship (2006-2011) in Dr. Tyler Jack's lab at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT), Boston, MA. Dr. Oliver joined the University of Utah and Huntsman Cancer Institute in 2011. She is now Associate Professor with tenure and a Huntsman Cancer Institute (HCI) Endowed Chair in Cancer Research in the Department of Oncological Sciences. Dr. Oliver is a co-leader of the Cell Response and Regulation (CRR) and co-leader of the Lung Cancer Disease Center at HCI. Dr. Oliver has received many awards including a National Science Foundation (NSF) graduate student fellowship, and two postdoctoral fellowships from ASPET-Merck and the Ludwig Foundation at MIT. As an independent investigator, she has received awards from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, American Cancer Society, American Lung Association, and was honored with a William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation (LCRF). Research: Dr. Oliver's research is devoted to understanding mechanisms of lung cancer biology with the goal of identifying novel therapeutic targets to improve patient outcome. As a graduate student at Duke, she studied the developmental origins of the childhood brain tumor, medulloblastoma, where she identified mechanisms of tumor progression in mouse models of the disease. As a postdoctoral fellow at MIT and as an independent investigator, she has developed novel mouse models of squamous and small cell lung cancer. Her work has contributed to our understanding of the Mdm2/p53 pathway, chemotherapy resistance mechanisms, and the functions of oncogenic transcription factors like Sox2, Nkx2-1, and Myc. Dr. Oliver’s laboratory integrates mouse genetics, molecular and cellular biology, biochemistry, single cell genomics, in vivo imaging, and preclinical therapeutics. Teaching and Mentoring: Dr. Oliver has been active in graduate student and medical school teaching. Dr. Oliver's trainees have received a number of prestigious awards. These include the Susan Cooper Jones Postdoc of the Year Award, the James W. Prahl Memorial Graduate Student of the Year award, an NIH NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. In addition, Oliver lab trainees have won a number of travel awards including to Keystone Symposia and selection as a recipient to the 68th Annual Lindau Nobel Laureate meeting in Germany.
106

Omics in SCLC

Presentations: 5 | 13:20 - 14:30 ET | 17:20 - 18:30 UTC
- 133
  
  Deciphering Tumor Evolution in Small Cell Lung Cancer
  
  13:20 - 13:32
  Speaker(s)
  
  Julie George
  Germany
  
  Julie George, PhD, is Professor of Molecular Head and Neck Oncology at the University of Cologne, Germany. She completed her PhD at the German Cancer Research Center in Heidelberg, Germany, before pursuing post-doctoral studies on cancer genomics at the University of Cologne. The focus of her research is to understand the biological processes of cancer and to study the evolutionary adaption of cancer to therapeutic response with a focus on small cell lung cancer (SCLC). Her work employs multi-disciplinary approaches for to study of patient tumors, which includes genome, transcriptome and single-cell sequencing technologies, computational evaluation of complex data sets, as well as functional characterization of patient-derived tumor models.
- 134
  
  Determination of Functional Impacts of Recurrent SCLC Mutations
  
  13:32 - 13:44
  Speaker(s)
  
  Dominic Rothwell
  United Kingdom
  
  Dr Dominic Graham Rothwell. NAB Team Leader, Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, UK. After obtaining a BSc (Hon) in Applied Genetics from the University of Liverpool I studied for my DPhil with Professor Ian Hickson at the Weatherall Institute, University of Oxford investigating the functional role DNA repair genes. After this I moved into more translational research, initially with Dr John Norton looking for molecular markers in multiple myeloma before joining Professor Robert Hawkins laboratory at the University of Manchester where I was responsible for developing molecular monitoring of immunotherapy trials including CAR T-cells and the establishment of a GCP compliant facility. In 2011 I joined the Nucleic Acid Biomarker (NAB) team of Professor Caroline Dive at the CRUK Manchester Institute and began my current research focus on the molecular analysis of blood borne biomarkers for use in cancer. This work focusses on utilising circulating free DNA (cfDNA) and circulating tumour cells (CTC) to enable the molecular characterisation of tumours at the genetic, epigenetic and transcriptional level from a patient blood sample. I took over as Team Leader of NAB in November 2019.
- 135
  
  Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer
  
  13:56 - 14:08
  Speaker(s)
  
  Siddhartha Devarakonda
  USA
- 136
  
  Multi-omic Analysis of Lung Tumors Defines Pathways Involved in Lineage Plasticity
  
  14:08 - 14:20
  Speaker(s)
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
- 137
  
  Panel Discussion with Q&A
  
  14:20 - 14:30
  Speaker(s)
  
  Julie George
  Germany
  
  Julie George, PhD, is Professor of Molecular Head and Neck Oncology at the University of Cologne, Germany. She completed her PhD at the German Cancer Research Center in Heidelberg, Germany, before pursuing post-doctoral studies on cancer genomics at the University of Cologne. The focus of her research is to understand the biological processes of cancer and to study the evolutionary adaption of cancer to therapeutic response with a focus on small cell lung cancer (SCLC). Her work employs multi-disciplinary approaches for to study of patient tumors, which includes genome, transcriptome and single-cell sequencing technologies, computational evaluation of complex data sets, as well as functional characterization of patient-derived tumor models.
  
  Siddhartha Devarakonda
  USA
  
  Trudy Oliver
  USA
  
  Dr. Oliver received her PhD from Duke University in 2005 in Pharmacology and Cancer Biology as a graduate student in Dr. Rob Wechsler-Reya's lab. She completed a Postdoctoral Fellowship (2006-2011) in Dr. Tyler Jack's lab at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT), Boston, MA. Dr. Oliver joined the University of Utah and Huntsman Cancer Institute in 2011. She is now Associate Professor with tenure and a Huntsman Cancer Institute (HCI) Endowed Chair in Cancer Research in the Department of Oncological Sciences. Dr. Oliver is a co-leader of the Cell Response and Regulation (CRR) and co-leader of the Lung Cancer Disease Center at HCI. Dr. Oliver has received many awards including a National Science Foundation (NSF) graduate student fellowship, and two postdoctoral fellowships from ASPET-Merck and the Ludwig Foundation at MIT. As an independent investigator, she has received awards from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, American Cancer Society, American Lung Association, and was honored with a William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation (LCRF). Research: Dr. Oliver's research is devoted to understanding mechanisms of lung cancer biology with the goal of identifying novel therapeutic targets to improve patient outcome. As a graduate student at Duke, she studied the developmental origins of the childhood brain tumor, medulloblastoma, where she identified mechanisms of tumor progression in mouse models of the disease. As a postdoctoral fellow at MIT and as an independent investigator, she has developed novel mouse models of squamous and small cell lung cancer. Her work has contributed to our understanding of the Mdm2/p53 pathway, chemotherapy resistance mechanisms, and the functions of oncogenic transcription factors like Sox2, Nkx2-1, and Myc. Dr. Oliver’s laboratory integrates mouse genetics, molecular and cellular biology, biochemistry, single cell genomics, in vivo imaging, and preclinical therapeutics. Teaching and Mentoring: Dr. Oliver has been active in graduate student and medical school teaching. Dr. Oliver's trainees have received a number of prestigious awards. These include the Susan Cooper Jones Postdoc of the Year Award, the James W. Prahl Memorial Graduate Student of the Year award, an NIH NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. In addition, Oliver lab trainees have won a number of travel awards including to Keystone Symposia and selection as a recipient to the 68th Annual Lindau Nobel Laureate meeting in Germany.
  
  Dominic Rothwell
  United Kingdom
  
  Dr Dominic Graham Rothwell. NAB Team Leader, Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, UK. After obtaining a BSc (Hon) in Applied Genetics from the University of Liverpool I studied for my DPhil with Professor Ian Hickson at the Weatherall Institute, University of Oxford investigating the functional role DNA repair genes. After this I moved into more translational research, initially with Dr John Norton looking for molecular markers in multiple myeloma before joining Professor Robert Hawkins laboratory at the University of Manchester where I was responsible for developing molecular monitoring of immunotherapy trials including CAR T-cells and the establishment of a GCP compliant facility. In 2011 I joined the Nucleic Acid Biomarker (NAB) team of Professor Caroline Dive at the CRUK Manchester Institute and began my current research focus on the molecular analysis of blood borne biomarkers for use in cancer. This work focusses on utilising circulating free DNA (cfDNA) and circulating tumour cells (CTC) to enable the molecular characterisation of tumours at the genetic, epigenetic and transcriptional level from a patient blood sample. I took over as Team Leader of NAB in November 2019.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
107

Biomarkers/ Liquid Biopsy/ Metastasis in SCLC

Presentations: 5 | 14:30 - 15:40 ET | 18:30 - 19:40 UTC
- 138
  
  Small Cell Lung Cancer Brain Metastases
  
  14:30 - 14:42
  Speaker(s)
  
  Ata Abbas
  USA
  
  Dr. Ata Abbas is a Research Scientist in the Division of Hematology and Oncology, Department of Medicine at Case Western Reserve University and an Associate Member of Case Comprehensive Cancer Center, Cleveland, Ohio. He has expertise in the areas of global transcriptional regulation, epigenetics, and genomics with a solid background in immunobiology. His current research is focused on 1) the identification of genomic, transcriptomic, and epigenomic signatures in SCLC metastases, and 2) understanding the mechanisms that SCLC utilizes to escape immune surveillance and to develop effective immunotherapeutic approaches to treat this highly metastatic malignancy.
- 139
  
  Neddylation Inhibition as a Therapeutic Vulnerability in SCLC
  
  14:42 - 14:54
  Speaker(s)
  
  David MacPherson
  USA
  
  Dr. MacPherson is a Professor in the Division of Human Biology at Fred Hutch. His lab is focused on understanding the molecular underpinnings of small cell lung cancer (SCLC). The lab studies SCLC patient samples and employs genetically engineered mouse (GEM) models as well as patient-derived xenograft models to interrogate genes that drive SCLC initiation, progression and response to therapy. Building upon the Rb/p53-deleted mouse model developed by Berns’ group, his lab has generated GEM models with deletions in SCLC tumor suppressors such as Pten, Crebbp and Max and with overexpression of oncogenes such as MYCN. His lab employs GEM and PDX models in therapeutic studies to understand and improve responses to novel and to standard therapies for SCLC.
- 140
  
  Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids
  
  14:54 - 15:06
  Speaker(s)
  
  Hiroyuki Yasuda
  Japan
  
  Hiroyuki Yasuda is an associate professor at Keio University, School of Medicine, Tokyo, Japan. He has focused on translational research in lung cancer field. Selected Publications: 1. Ishioka K, Yasuda H*, ….., Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 81(14):3916-3929, 2021. 2. Kawasaki K, ……., Yasuda H, …….. Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell. 183(5):1420-1435.e21, 2020. 3. Ikemura S, Yasuda H*, ………, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 116(20):10025-10030. 2019. 4. Yasuda H, …….Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 5(216):216ra177. 2013. 5. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 13(1):e23-31. 2012. * Corresponding author
- 141
  
  SLFN11 in SCLC
  
  15:06 - 15:18
  Speaker(s)
  
  Yves Pommier
  USA
- 142
  
  Panel Discussion with Q&A
  
  15:18 - 15:30
  Speaker(s)
  
  Ata Abbas
  USA
  
  Dr. Ata Abbas is a Research Scientist in the Division of Hematology and Oncology, Department of Medicine at Case Western Reserve University and an Associate Member of Case Comprehensive Cancer Center, Cleveland, Ohio. He has expertise in the areas of global transcriptional regulation, epigenetics, and genomics with a solid background in immunobiology. His current research is focused on 1) the identification of genomic, transcriptomic, and epigenomic signatures in SCLC metastases, and 2) understanding the mechanisms that SCLC utilizes to escape immune surveillance and to develop effective immunotherapeutic approaches to treat this highly metastatic malignancy.
  
  David MacPherson
  USA
  
  Dr. MacPherson is a Professor in the Division of Human Biology at Fred Hutch. His lab is focused on understanding the molecular underpinnings of small cell lung cancer (SCLC). The lab studies SCLC patient samples and employs genetically engineered mouse (GEM) models as well as patient-derived xenograft models to interrogate genes that drive SCLC initiation, progression and response to therapy. Building upon the Rb/p53-deleted mouse model developed by Berns’ group, his lab has generated GEM models with deletions in SCLC tumor suppressors such as Pten, Crebbp and Max and with overexpression of oncogenes such as MYCN. His lab employs GEM and PDX models in therapeutic studies to understand and improve responses to novel and to standard therapies for SCLC.
  
  Yves Pommier
  USA
  
  Hiroyuki Yasuda
  Japan
  
  Hiroyuki Yasuda is an associate professor at Keio University, School of Medicine, Tokyo, Japan. He has focused on translational research in lung cancer field. Selected Publications: 1. Ishioka K, Yasuda H*, ….., Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 81(14):3916-3929, 2021. 2. Kawasaki K, ……., Yasuda H, …….. Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell. 183(5):1420-1435.e21, 2020. 3. Ikemura S, Yasuda H*, ………, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 116(20):10025-10030. 2019. 4. Yasuda H, …….Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 5(216):216ra177. 2013. 5. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 13(1):e23-31. 2012. * Corresponding author
108

Novel Pathways and Targets in SCLC - Session 1

Presentations: 5 | 15:40 - 16:50 ET | 19:40 - 20:50 UTC
- 143
  
  Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors
  
  15:40 - 15:52
  Speaker(s)
  
  Benjamin Lok
  Canada
  
  Dr. Benjamin Lok is a Clinician-Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Radiation Oncology, Medical Biophysics, and the Institute of Medical Science, at the University of Toronto. He received his MD from New York University School of Medicine in 2012 followed by clinical residency with laboratory research training at Memorial Sloan Kettering Cancer Center. Since joining Princess Margaret in 2017, Dr. Lok has served as Staff Radiation Oncologist within the Lung Site Group. He leads a CIHR and NIH funded laboratory program with a mission to improve outcomes for lung cancer patients by understanding mechanisms of resistance and developing novel therapeutic strategies, particularly those related to DNA repair.
- 144
  
  Radioimmunotherapy Targeting Delta-Like Ligand 3 in SCLC
  
  15:52 - 16:04
  Speaker(s)
  
  Kathryn Tully
  USA
  
  Kathryn Tully was raised in Manchester, NH and attended Trinity College for her undergraduate degree, where she received her B.S. in Biochemistry in 2016. Kathryn is currently a fifth year Ph.D. Candidate in the Pharmacology program at the Weill Cornell Graduate School of Medical Sciences. She is performing her dissertation research in the laboratories of Charles M. Rudin and Jason S. Lewis, where her research focuses on developing immunoPET tracers and radioimmunotherapy agents for the imaging and treatment of small cell lung cancer.
- 145
  
  Regulation of SCLC Neuroendocrine Plasticity by the RNA-Binding Protein ZFP36L1
  
  16:04 - 16:16
  Speaker(s)
  
  Matthew Oser
  USA
  
  Matthew G. Oser MD, PhD, is a Physician-Scientist in the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI) and an Assistant Professor of Medicine at Harvard Medical School. After earning his MD and PhD from the Albert Einstein College of Medicine, Dr. Oser completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed medical oncology fellowship training at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program, and performed his post-doctoral work in Dr. William G. Kaelin Jr’s laboratory at DFCI. Since 2019, he is the principal investigator of his own laboratory at DFCI. Dr. Oser’s research focuses on using CRISPR/Cas9 to understand mechanisms that control neuroendocrine differentiation in SCLC and to identify novel targeted therapies for SCLC. Dr. Oser has been the recipient of a Lung Cancer Research Foundation Career Development Award, a NIH K08 career development award, and a Damon Runyon Clinical Investigator Award.
- 146
  
  Microenvironmental Interactions Between SCLC and Neurons
  
  16:28 - 16:40
  Speaker(s)
  
  Humsa Venkatesh
  USA
  
  Humsa Venkatesh received her undergraduate degree in Chemical Biology from the University of California, Berkeley and her PhD in Cancer Biology from Stanford University. After completing her postdoctoral work, she joined the Stanford faculty in 2019 and is now starting her Cancer Neuroscience research program as Assistant Professor at the Brigham and Women’s Hospital and Harvard Medical School. She has been recognized by the MIT Technology Review as a Pioneer Under 35 ‘TR35’ (2018), by Genetic Engineering News as a ‘Top 10 innovator to watch under 40’ (2019), and won the Science & SciLife Prize for Young Scientists (2019).
  
  Dr. Venkatesh’s research studies the reciprocal interactions between the central nervous system and brain cancers. Her work emphasizes the electrical components of glioma pathophysiology and highlights the extent to which the brain and its neurons can control and facilitate disease progression. The understanding of these co-opting mechanisms has led to novel strategies to broadly treat cancers, by disabling their ability to electrically integrate into neural circuitry. Her pioneering research in this emerging field of cancer neuroscience aims to harness the systems level microenvironmental dependencies of tumor growth to develop innovative therapeutic treatments.
- 147
  
  Panel Discussion with Q&A
  
  16:40 - 16:50
  Speaker(s)
  
  Lauren Byers
  USA
  
  Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas. She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences. She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group. Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards, the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award, and most recently, membership of The American Society for Clinical Investigation (ASCI). As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC. Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models. Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models (published in Cancer Cell 2021 and Nature Cancer 2020).
  
  Benjamin Lok
  Canada
  
  Dr. Benjamin Lok is a Clinician-Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Radiation Oncology, Medical Biophysics, and the Institute of Medical Science, at the University of Toronto. He received his MD from New York University School of Medicine in 2012 followed by clinical residency with laboratory research training at Memorial Sloan Kettering Cancer Center. Since joining Princess Margaret in 2017, Dr. Lok has served as Staff Radiation Oncologist within the Lung Site Group. He leads a CIHR and NIH funded laboratory program with a mission to improve outcomes for lung cancer patients by understanding mechanisms of resistance and developing novel therapeutic strategies, particularly those related to DNA repair.
  
  Matthew Oser
  USA
  
  Matthew G. Oser MD, PhD, is a Physician-Scientist in the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI) and an Assistant Professor of Medicine at Harvard Medical School. After earning his MD and PhD from the Albert Einstein College of Medicine, Dr. Oser completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed medical oncology fellowship training at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program, and performed his post-doctoral work in Dr. William G. Kaelin Jr’s laboratory at DFCI. Since 2019, he is the principal investigator of his own laboratory at DFCI. Dr. Oser’s research focuses on using CRISPR/Cas9 to understand mechanisms that control neuroendocrine differentiation in SCLC and to identify novel targeted therapies for SCLC. Dr. Oser has been the recipient of a Lung Cancer Research Foundation Career Development Award, a NIH K08 career development award, and a Damon Runyon Clinical Investigator Award.
  
  Kathryn Tully
  USA
  
  Kathryn Tully was raised in Manchester, NH and attended Trinity College for her undergraduate degree, where she received her B.S. in Biochemistry in 2016. Kathryn is currently a fifth year Ph.D. Candidate in the Pharmacology program at the Weill Cornell Graduate School of Medical Sciences. She is performing her dissertation research in the laboratories of Charles M. Rudin and Jason S. Lewis, where her research focuses on developing immunoPET tracers and radioimmunotherapy agents for the imaging and treatment of small cell lung cancer.
  
  Humsa Venkatesh
  USA
  
  Humsa Venkatesh received her undergraduate degree in Chemical Biology from the University of California, Berkeley and her PhD in Cancer Biology from Stanford University. After completing her postdoctoral work, she joined the Stanford faculty in 2019 and is now starting her Cancer Neuroscience research program as Assistant Professor at the Brigham and Women’s Hospital and Harvard Medical School. She has been recognized by the MIT Technology Review as a Pioneer Under 35 ‘TR35’ (2018), by Genetic Engineering News as a ‘Top 10 innovator to watch under 40’ (2019), and won the Science & SciLife Prize for Young Scientists (2019).
  
  Dr. Venkatesh’s research studies the reciprocal interactions between the central nervous system and brain cancers. Her work emphasizes the electrical components of glioma pathophysiology and highlights the extent to which the brain and its neurons can control and facilitate disease progression. The understanding of these co-opting mechanisms has led to novel strategies to broadly treat cancers, by disabling their ability to electrically integrate into neural circuitry. Her pioneering research in this emerging field of cancer neuroscience aims to harness the systems level microenvironmental dependencies of tumor growth to develop innovative therapeutic treatments.
109

Clinical Trials in SCLC

Presentations: 4 | 16:50 - 17:50 ET | 20:50 - 21:50 UTC
- 148
  
  Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis
  
  16:50 - 17:02
  Speaker(s)
  
  Catherine Meador
  USA
  
  Dr. Catherine Meador is a senior clinical fellow in the Dana-Farber/Mass General Brigham medical oncology fellowship program. Her primary research interests focus on the biology of initiation and progression of small cell lung cancer, as well as mechanisms of histologic transformation in lung cancer and the pathologic and clinical characteristics of mixed histology lung tumors.
- 149
  
  Clinical Trials in SCLC Immunotherapy
  
  17:02 - 17:14
  Speaker(s)
  
  Luis Paz-Ares
  Spain
  
  Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid. He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000). Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.
- 150
  
  Inflamed Subtype of SCLC and Clinical Implications
  
  17:14 - 17:26
  Speaker(s)
  
  Taofeek Owonikoko
  USA
  
  Dr. Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University. He is also a Georgia Research Alliance Distinguished Cancer Scientist. He received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000. He was a postdoctoral research fellow at the Johns Hopkins University in Baltimore, USA from 2000 to 2002. He completed Internal Medicine residency training at the Graduate Hospital, Drexel University in Philadelphia in 2005 followed by a clinical fellowship in Hematology/Medical Oncology at the University of Pittsburgh in 2008. He has been on faculty at Emory University since 2008 and has focused his translational research activities on lung cancer, thyroid cancer and early phase drug development. Dr. Owonikoko has received peer-reviewed grant funding from the NIH, DOD and Georgia Cancer Coalition. He has published over 230 peer-reviewed manuscripts in high impact journals including New England Journal of Medicine, Cell, Science, Nature, CA Cancer Journal, Cancer Cell, Lancet Oncology, JCO, Cancer Discovery, Nature Communications, Oncogene, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.
- 152
  
  Panel Discussion with Q&A
  
  17:26 - 17:55
  Speaker(s)
  
  Kristin Higgins
  USA
  
  Kristin Higgins, M.D., specializes in the treatment of lung and head and neck cancers. She completed residency in Radiation Oncology at Duke University, as well as an internship in internal medicine. She attended medical school at Tulane Univer-sity in New Orleans, LA. She earned a B.S. in neuroscience at Van-derbilt University and graduated magna cum laude. Throughout her training Dr. Higgins received numerous honors, including in-duction into Alpha Omega Alpha Honor Medical Society, and the Roentgen Resident/Fellow Research Award at Duke University, and the ASCO Bradley Stuart Beller Merit Award. Dr. Higgins is an Associate Professor within the Emory School of Medicine and serves as the Medical Director of Radiation Oncolo-gy at the main campus location. She leads numerous Winship Clinical Trials that examine innovative treatment approaches in the treatment of lung cancer. One such clinical trial is LU005, A NRG Oncology/Alliance study comparing chemoradiation with or without immunotherapy for limited stage small cell lung cancer. This clinical trial is funded by the National Cancer Institute and provides a novel treatment approach for patients with newly diagnosed small cell lung cancer. Dr. Higgins has authored and coauthored over 60 scientific, peer-reviewed manuscripts and abstracts and given many oral presentations at national and international meetings. Dr. Higgins is a member of multiple professional organizations including the American Society for Radiation Oncology, the American Board of Radiology, the International Association for the study of Lung Cancer, The American Society of Clinical Oncology, and the Radiation Therapy Oncology Group. In her free time, Dr. Higgins enjoys spending time with her husband Darren and her small children, Hunter and Parker. She also enjoys running, traveling, reading, fine dining, and wine tasting.
  
  Victoria Lai
  USA
  
  Victoria Lai is an assistant attending at Memorial Sloan Kettering with a research and clinical focus on small cell lung lung cancer and other pulmonary neuroendocrine malignancies.
  
  Catherine Meador
  USA
  
  Dr. Catherine Meador is a senior clinical fellow in the Dana-Farber/Mass General Brigham medical oncology fellowship program. Her primary research interests focus on the biology of initiation and progression of small cell lung cancer, as well as mechanisms of histologic transformation in lung cancer and the pathologic and clinical characteristics of mixed histology lung tumors.
  
  Trudy Oliver
  USA
  
  Dr. Oliver received her PhD from Duke University in 2005 in Pharmacology and Cancer Biology as a graduate student in Dr. Rob Wechsler-Reya's lab. She completed a Postdoctoral Fellowship (2006-2011) in Dr. Tyler Jack's lab at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT), Boston, MA. Dr. Oliver joined the University of Utah and Huntsman Cancer Institute in 2011. She is now Associate Professor with tenure and a Huntsman Cancer Institute (HCI) Endowed Chair in Cancer Research in the Department of Oncological Sciences. Dr. Oliver is a co-leader of the Cell Response and Regulation (CRR) and co-leader of the Lung Cancer Disease Center at HCI. Dr. Oliver has received many awards including a National Science Foundation (NSF) graduate student fellowship, and two postdoctoral fellowships from ASPET-Merck and the Ludwig Foundation at MIT. As an independent investigator, she has received awards from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, American Cancer Society, American Lung Association, and was honored with a William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation (LCRF). Research: Dr. Oliver's research is devoted to understanding mechanisms of lung cancer biology with the goal of identifying novel therapeutic targets to improve patient outcome. As a graduate student at Duke, she studied the developmental origins of the childhood brain tumor, medulloblastoma, where she identified mechanisms of tumor progression in mouse models of the disease. As a postdoctoral fellow at MIT and as an independent investigator, she has developed novel mouse models of squamous and small cell lung cancer. Her work has contributed to our understanding of the Mdm2/p53 pathway, chemotherapy resistance mechanisms, and the functions of oncogenic transcription factors like Sox2, Nkx2-1, and Myc. Dr. Oliver’s laboratory integrates mouse genetics, molecular and cellular biology, biochemistry, single cell genomics, in vivo imaging, and preclinical therapeutics. Teaching and Mentoring: Dr. Oliver has been active in graduate student and medical school teaching. Dr. Oliver's trainees have received a number of prestigious awards. These include the Susan Cooper Jones Postdoc of the Year Award, the James W. Prahl Memorial Graduate Student of the Year award, an NIH NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. In addition, Oliver lab trainees have won a number of travel awards including to Keystone Symposia and selection as a recipient to the 68th Annual Lindau Nobel Laureate meeting in Germany.
  
  Taofeek Owonikoko
  USA
  
  Dr. Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University. He is also a Georgia Research Alliance Distinguished Cancer Scientist. He received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000. He was a postdoctoral research fellow at the Johns Hopkins University in Baltimore, USA from 2000 to 2002. He completed Internal Medicine residency training at the Graduate Hospital, Drexel University in Philadelphia in 2005 followed by a clinical fellowship in Hematology/Medical Oncology at the University of Pittsburgh in 2008. He has been on faculty at Emory University since 2008 and has focused his translational research activities on lung cancer, thyroid cancer and early phase drug development. Dr. Owonikoko has received peer-reviewed grant funding from the NIH, DOD and Georgia Cancer Coalition. He has published over 230 peer-reviewed manuscripts in high impact journals including New England Journal of Medicine, Cell, Science, Nature, CA Cancer Journal, Cancer Cell, Lancet Oncology, JCO, Cancer Discovery, Nature Communications, Oncogene, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.
  
  Luis Paz-Ares
  Spain
  
  Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid. He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000). Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.
110

Day 1 Closing

Presentations: 1 | 17:50 - 18:00 ET | 21:50 - 22:00 UTC
- 153
  
  Day 1 Closing
  
  17:55 - 18:00
  Speaker(s)
  
  Charlie Rudin
  USA
  
  Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
111

Satellite CME Symposium By PeerView: Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Presentations: 1 | 18:05 - 19:05 ET | 22:05 - 23:05 UTC
- 154
  
  Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next? (Watch this presentation at PeerView.com/SCLC2021-Virtual)
  
  18:05 - 19:05
  Speaker(s)
  
  Satellite CME Symposium By PeerView (External Link)
  
  Access presentation at PeerView.com/SCLC2021-Virtual.

1635519600000

Charlie Rudin

USA

IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer - Day 1

Charlie Rudin

USA

Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.

Heather Wakelee

USA

Dr. Heather Wakelee is the Chief and Professor of Medicine in the Division of Oncology at Stanford University. She is also the Deputy Director of the Stanford Cancer Institute. Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. She is also involved in trials of adjuvant therapy, immunotherapy and anti-angiogenesis agents in addition to collaborations with colleagues focused in biomarkers and others focused in population science research. Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as the President-elect for the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO).

Katie Maher

USA

Katie Maher joins the IASLC as its Member Experience Coordinator. A graduate of Colorado State University in Business Administration, Katie has a wide array of diverse experience in marketing, content creation, customer service and event planning. And as part of the Member Experience team, Katie will provide incredible support to our members, meeting attendees, partners and other stakeholders.

1635602400

1635632400

IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer - Day 2

Saturday, October 30
10:00 - 18:20 ET | 14:00 - 22:20 UTC | Local Time

112

Early Career Session

Presentations: 7 | 10:00 - 11:20 ET | 14:00 - 15:20 UTC
- 155
  
  MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
  
  10:00 - 10:10
  Speaker(s)
  
  Abbie Ireland
  USA
  
  Abbie Ireland is a PhD student in Dr. Trudy Oliver’s lab at Huntsman Cancer Institute at University of Utah. She studies modes of transcriptional and metabolic plasticity in SCLC and is currently funded by an NIH T32 Developmental Biology training grant.
- 156
  
  XPO1 as a Target for Chemoresistance in SCLC
  
  10:10 - 10:20
  Speaker(s)
  
  Alvaro Quintanal Villalonga
  USA
  
  Alvaro Quintanal Villalonga is a lung cancer researcher with translational and basic research experience in the field of molecular oncology and targeted therapies, with a special focus on overcoming therapy resistance and combination therapies. During his PhD at the Spanish National Cancer Research Center (CNIO) he studied the role of the tyrosine kinase receptors FGFR (Fibroblast Growth Factor Receptor)1 and FGFR4 in lung cancer. He demonstrated that the pro-oncogenic effects of both FGFRs is conditional and described the molecular contexts in which these are pro-tumoral. On these projects they identified biomarkers of response to FGFR inhibitors (FGFRi) in monotherapy and described the high efficacy of the combination of EGFRis and FGFRis in a subset of non-small cell lung cancer (NSCLC) patients, leading to the initiation of two phase I/II clinical trials with these inhibitors and one patents application. In addition, he led other basic/translational projects related to topics including prognostic/predictive biomarker identification, platinum resistance and novel therapies for lung cancer. In March 2018, Dr. Quintanal Villalonga was recruited by Memorial Sloan Kettering Cancer Center to join Dr. Rudin’s lab, where he focuses his research on the identification of molecular drivers of lineage plasticity in lung cancer leading to histological transdifferentiation from adenocarcinoma to either squamous or small cell carcinoma (SCLC); in the single cell transcriptomic characterization of SCLC; and in the identification of novel therapeutic targets in SCLC, with a focus on chemotherapy resistance.
- 157
  
  Profiling of the cfDNA Methylome for Detection and Subtyping of Small Cell Lung Cancers
  
  10:20 - 10:30
  Speaker(s)
  
  Francesca Chemi
  United Kingdom
- 158
  
  Targeting CDK7 to Enhance Immunity in Small Cell Lung Cancer
  
  10:30 - 10:40
  Speaker(s)
  
  Hua Zhang
  USA
  
  I am an Instructor in the Dr. Kwok-Kin Wong’s laboratory at Perlmutter Cancer Center of NYU Langone Health. I have been leading the efforts to establish new murine models for oncoimmunology studies in lung cancer, as well as studying the role of cyclin dependent kinases (CDKs) in immunity. My main research focus is to utilize these immunocompetent murine models to study the immune tumor microenvironment (TME), to identify targets to enhance immunotherapy and to dissect the underlying mechanism leading to immune evasion, particularly in the field of small cell lung cancer (SCLC). My work in SCLC aims to improve our knowledge of dysregulated immune milieu and to provide a rationale for new combination regimens in patients.
- 159
  
  To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer
  
  10:50 - 11:00
  Speaker(s)
  
  Portia Thomas
  USA
  
  Portia Thomas is an M.D./Ph.D. student at Meharry Medical College in Nashville, TN. Dr. Thomas graduated summa cum laude with departmental honors, earning a B.S. in Chemistry and B.A. in Biology from Erskine College in Due West, SC. She recently defended her thesis work under the mentorship of Christine Lovly, M.D., Ph.D. at Vanderbilt-Ingram Cancer Center. Dr. Thomas's work focused on profiling the immune microenvironment of SCLC in efforts to improve the application of immunotherapy in this disease. Her long-term career aspiration is to be a pediatric oncologist, researching immunotherapeutic strategies for pediatric high-risk solid tumors.
- 160
  
  Molecular Subtyping of SCLC in Tumor Tissues and CTCs
  
  11:00 - 11:10
  Speaker(s)
  
  Prasad Kopparapu
  USA
  
  Prasad Kopparapu Bio: Dr. Prasad Kopparapu is a research fellow in Dr. Christine Lovly’s lab at vanderbilt university medical center, studying circulating tumor cells in small cell lung cancer patients. Dr. Kopparapu got his PhD in Toxicology from Oregon state university where he worked on small molecule functional converters of anti-apoptotic Bcl-2 protein. Before coming to USA for his graduate studies Dr. Kopparapu worked in India as a clinical programmer. Dr. Kopparapu did his bachelor’s in chemical engineering from Osmania university and a master’s in biotechnology from JNT University in his hometown Hyderabad in India. In his free time Dr. Kopparapu likes spending time in nature and is also a yoga practitioner.
- 161
  
  Panel Discussion with Q&A
  
  11:10 - 11:30
  Speaker(s)
  
  Francesca Chemi
  United Kingdom
  
  Abbie Ireland
  USA
  
  Abbie Ireland is a PhD student in Dr. Trudy Oliver’s lab at Huntsman Cancer Institute at University of Utah. She studies modes of transcriptional and metabolic plasticity in SCLC and is currently funded by an NIH T32 Developmental Biology training grant.
  
  Prasad Kopparapu
  USA
  
  Prasad Kopparapu Bio: Dr. Prasad Kopparapu is a research fellow in Dr. Christine Lovly’s lab at vanderbilt university medical center, studying circulating tumor cells in small cell lung cancer patients. Dr. Kopparapu got his PhD in Toxicology from Oregon state university where he worked on small molecule functional converters of anti-apoptotic Bcl-2 protein. Before coming to USA for his graduate studies Dr. Kopparapu worked in India as a clinical programmer. Dr. Kopparapu did his bachelor’s in chemical engineering from Osmania university and a master’s in biotechnology from JNT University in his hometown Hyderabad in India. In his free time Dr. Kopparapu likes spending time in nature and is also a yoga practitioner.
  
  Benjamin Lok
  Canada
  
  Dr. Benjamin Lok is a Clinician-Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Radiation Oncology, Medical Biophysics, and the Institute of Medical Science, at the University of Toronto. He received his MD from New York University School of Medicine in 2012 followed by clinical residency with laboratory research training at Memorial Sloan Kettering Cancer Center. Since joining Princess Margaret in 2017, Dr. Lok has served as Staff Radiation Oncologist within the Lung Site Group. He leads a CIHR and NIH funded laboratory program with a mission to improve outcomes for lung cancer patients by understanding mechanisms of resistance and developing novel therapeutic strategies, particularly those related to DNA repair.
  
  Alvaro Quintanal Villalonga
  USA
  
  Alvaro Quintanal Villalonga is a lung cancer researcher with translational and basic research experience in the field of molecular oncology and targeted therapies, with a special focus on overcoming therapy resistance and combination therapies. During his PhD at the Spanish National Cancer Research Center (CNIO) he studied the role of the tyrosine kinase receptors FGFR (Fibroblast Growth Factor Receptor)1 and FGFR4 in lung cancer. He demonstrated that the pro-oncogenic effects of both FGFRs is conditional and described the molecular contexts in which these are pro-tumoral. On these projects they identified biomarkers of response to FGFR inhibitors (FGFRi) in monotherapy and described the high efficacy of the combination of EGFRis and FGFRis in a subset of non-small cell lung cancer (NSCLC) patients, leading to the initiation of two phase I/II clinical trials with these inhibitors and one patents application. In addition, he led other basic/translational projects related to topics including prognostic/predictive biomarker identification, platinum resistance and novel therapies for lung cancer. In March 2018, Dr. Quintanal Villalonga was recruited by Memorial Sloan Kettering Cancer Center to join Dr. Rudin’s lab, where he focuses his research on the identification of molecular drivers of lineage plasticity in lung cancer leading to histological transdifferentiation from adenocarcinoma to either squamous or small cell carcinoma (SCLC); in the single cell transcriptomic characterization of SCLC; and in the identification of novel therapeutic targets in SCLC, with a focus on chemotherapy resistance.
  
  Portia Thomas
  USA
  
  Portia Thomas is an M.D./Ph.D. student at Meharry Medical College in Nashville, TN. Dr. Thomas graduated summa cum laude with departmental honors, earning a B.S. in Chemistry and B.A. in Biology from Erskine College in Due West, SC. She recently defended her thesis work under the mentorship of Christine Lovly, M.D., Ph.D. at Vanderbilt-Ingram Cancer Center. Dr. Thomas's work focused on profiling the immune microenvironment of SCLC in efforts to improve the application of immunotherapy in this disease. Her long-term career aspiration is to be a pediatric oncologist, researching immunotherapeutic strategies for pediatric high-risk solid tumors.
  
  Hua Zhang
  USA
  
  I am an Instructor in the Dr. Kwok-Kin Wong’s laboratory at Perlmutter Cancer Center of NYU Langone Health. I have been leading the efforts to establish new murine models for oncoimmunology studies in lung cancer, as well as studying the role of cyclin dependent kinases (CDKs) in immunity. My main research focus is to utilize these immunocompetent murine models to study the immune tumor microenvironment (TME), to identify targets to enhance immunotherapy and to dissect the underlying mechanism leading to immune evasion, particularly in the field of small cell lung cancer (SCLC). My work in SCLC aims to improve our knowledge of dysregulated immune milieu and to provide a rationale for new combination regimens in patients.
113

Welcome and Keynote

Presentations: 3 | 11:30 - 12:05 ET | 15:30 - 16:05 UTC
- 162
  
  Welcome
  
  11:30 - 11:33
  Speaker(s)
  
  Charlie Rudin
  USA
  
  Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
- 163
  
  Keynote: Lessons from Mouse Models
  
  11:33 - 11:55
  Speaker(s)
  
  Julien Sage
  USA
  
  Dr. Sage trained at the University of Nice (PhD) in France and MIT (post-doc) before starting his research group at Stanford University in 2004. He is currently the Elaine and John Chambers Professor of Pediatric Cancer at Stanford and serves as the co-Director of the Cancer Biology PhD program. The Sage lab is fundamentally interested in the mechanism driving the proliferation of cells. Dr. Sage has been working for many years now on the RB tumor suppressor and how loss of RB promotes tumorigenesis in children and adult patients. Dr. Sage became initially interested in small cell lung cancer (SCLC) because of the nearly ubiquitous loss of RB in this cancer type and the intriguing relationship in mice and humans between loss of RB and the growth of neuroendocrine lesions. In the past few years, the Sage lab has developed pre-clinical models for SCLC and has used these models to investigate signaling pathways driving the growth of this cancer type as well as the mechanisms underlying how SCLC tumors become resistant to therapy.
- 164
  
  Keynote Discussion with Q&A
  
  11:55 - 12:10
  Speaker(s)
  
  Julien Sage
  USA
  
  Dr. Sage trained at the University of Nice (PhD) in France and MIT (post-doc) before starting his research group at Stanford University in 2004. He is currently the Elaine and John Chambers Professor of Pediatric Cancer at Stanford and serves as the co-Director of the Cancer Biology PhD program. The Sage lab is fundamentally interested in the mechanism driving the proliferation of cells. Dr. Sage has been working for many years now on the RB tumor suppressor and how loss of RB promotes tumorigenesis in children and adult patients. Dr. Sage became initially interested in small cell lung cancer (SCLC) because of the nearly ubiquitous loss of RB in this cancer type and the intriguing relationship in mice and humans between loss of RB and the growth of neuroendocrine lesions. In the past few years, the Sage lab has developed pre-clinical models for SCLC and has used these models to investigate signaling pathways driving the growth of this cancer type as well as the mechanisms underlying how SCLC tumors become resistant to therapy.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
114

Subtypes/ Biomarkers in SCLC

Presentations: 5 | 12:10 - 13:20 ET | 16:10 - 17:20 UTC
- 165
  
  Histological Subtyping of SCLC
  
  12:10 - 12:22
  Speaker(s)
  
  Natasha Rekhtman
  USA
  
  Dr. Rekhtman received a Bachelor’s degree from New York University (New York, NY) and an MD, PhD degree from Albert Einstein College of Medicine (Bronx, NY) with the Alpha Omega Alpha distinction and the award from the American Medical Women Association. She completed residency in pathology and a fellowship in surgical pathology at the Johns Hopkins Hospital (Baltimore, MD), followed by a cytopathology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY). After completing training in 2008, she joined MSKCC as a thoracic pathologist and cytopathologist, where she currently serves as an Attending Pathologist. Dr. Rekhtman’s research focuses on histopathologic, immunohistochemical, and molecular aspects of thoracic tumors, with the goal to advance the diagnostic criteria and define clinically relevant subsets and biomarkers. She has a special interest in investigating characteristics of lung carcinomas defined by specific genomic alterations and neuroendocrine cancers. Dr. Rekhtman has published over 150 papers and multiple book chapters. She is the main editor and author of the book titled “Quick Reference Handbook for Surgical Pathologists”, the 2nd edition of which was published in 2019. Dr. Rekhtman has been an invited speaker at multiple national and international conferences, and serves as a co-director of the annual MSKCC/Massachusetts General Hospital course on thoracic pathology. She is a member of the NCI Steering Committee for Thoracic Malignancies and International Association for the Study of Lung Cancer pathology panel, among others. She is a member of Editorial Boards of several journals, and serves as an Associated Editor at Modern Pathology.
- 166
  
  SCLC Subgroups and Their Potential Clinical Significance
  
  12:22 - 12:34
  Speaker(s)
  
  Carl Gay
  USA
  
  Dr. Gay graduated from Johns Hopkins University in 2005 (BA, Biology) and then enrolled at New York University School of Medicine, where he obtained his PhD (2011, Cellular & Molecular Biology) and MD (2013) degrees. He completed his residency at the University of Texas Health Science Center at Houston before joining MD Anderson Cancer Center in 2015 as a clinical fellow. In 2019, Dr. Gay was appointed Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology. As a clinical investigator, Dr. Gay designs and oversees clinical trials for a variety of thoracic malignancies with a particular focus in small cell lung cancer. Dr. Gay’s research includes identifying novel therapeutics and predictive biomarkers for patients with small cell lung cancer.
- 167
  
  Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns
  
  12:34 - 12:46
  Speaker(s)
  
  Simon Heeke
  USA
  
  Simon Heeke received a Bachelor and Master’s degree in Molecular Medicine at the Medical University of Innsbruck in Austria, prior to a PhD from the University Côte d’Azur in Nice, France. In 2020, he became a Postdoctoral Fellow in the laboratory of John V. Heymach in the Department of Thoracic H&N Medical Oncology at the University of Texas MD Anderson Cancer Center where he is focusing on innovative biomarker development in lung cancer with a focus on small-cell lung cancer. He has a specific interest in liquid biopsies and using advanced computational methods to condense relevant clinical information out of increasingly complex data to advance precision medicine and diagnostics.
- 168
  
  SCLC Biomarkers for Lung Cancer Screening
  
  12:46 - 12:58
  Speaker(s)
  
  Samir Hanash
  USA
  
  Dr. Hanash joined MD Anderson in July 2012 to lead the McCombs Institute for Cancer Early Detection and Treatment. He was previously program head for Molecular Diagnostics at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Hanash’s interests and expertise focus on the development and application of integrated approaches for the molecular profiling of cancer, with particular emphasis on the development of biomarkers for cancer early detection. A major focus has been on the development of blood based biomarkers for the early detection of lung cancer.
- 169
  
  Panel Discussion with Q&A
  
  12:58 - 13:20
  Speaker(s)
  
  Carl Gay
  USA
  
  Dr. Gay graduated from Johns Hopkins University in 2005 (BA, Biology) and then enrolled at New York University School of Medicine, where he obtained his PhD (2011, Cellular & Molecular Biology) and MD (2013) degrees. He completed his residency at the University of Texas Health Science Center at Houston before joining MD Anderson Cancer Center in 2015 as a clinical fellow. In 2019, Dr. Gay was appointed Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology. As a clinical investigator, Dr. Gay designs and oversees clinical trials for a variety of thoracic malignancies with a particular focus in small cell lung cancer. Dr. Gay’s research includes identifying novel therapeutics and predictive biomarkers for patients with small cell lung cancer.
  
  Samir Hanash
  USA
  
  Dr. Hanash joined MD Anderson in July 2012 to lead the McCombs Institute for Cancer Early Detection and Treatment. He was previously program head for Molecular Diagnostics at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Hanash’s interests and expertise focus on the development and application of integrated approaches for the molecular profiling of cancer, with particular emphasis on the development of biomarkers for cancer early detection. A major focus has been on the development of blood based biomarkers for the early detection of lung cancer.
  
  Simon Heeke
  USA
  
  Simon Heeke received a Bachelor and Master’s degree in Molecular Medicine at the Medical University of Innsbruck in Austria, prior to a PhD from the University Côte d’Azur in Nice, France. In 2020, he became a Postdoctoral Fellow in the laboratory of John V. Heymach in the Department of Thoracic H&N Medical Oncology at the University of Texas MD Anderson Cancer Center where he is focusing on innovative biomarker development in lung cancer with a focus on small-cell lung cancer. He has a specific interest in liquid biopsies and using advanced computational methods to condense relevant clinical information out of increasingly complex data to advance precision medicine and diagnostics.
  
  Jane Johnson
  USA
  
  Dr. Jane E. Johnson is a Professor in the Department of Neuroscience at the University of Texas Southwestern Medical Center where she holds the Shirley and William S. McIntyre Distinguished Chair in Neuroscience. She trained at the University of Washington in Seattle and the California Institute of Technology in Pasadena in molecular and developmental biology. Her contributions to science are in the transcriptional control of neural development and cancer, with recent work on lineage transcription factors defining subtypes of neuroendocrine lung cancer. She is a 2017 MERIT award recipient for her research on the transcriptional control of spinal cord development.
  
  Natasha Rekhtman
  USA
  
  Dr. Rekhtman received a Bachelor’s degree from New York University (New York, NY) and an MD, PhD degree from Albert Einstein College of Medicine (Bronx, NY) with the Alpha Omega Alpha distinction and the award from the American Medical Women Association. She completed residency in pathology and a fellowship in surgical pathology at the Johns Hopkins Hospital (Baltimore, MD), followed by a cytopathology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY). After completing training in 2008, she joined MSKCC as a thoracic pathologist and cytopathologist, where she currently serves as an Attending Pathologist. Dr. Rekhtman’s research focuses on histopathologic, immunohistochemical, and molecular aspects of thoracic tumors, with the goal to advance the diagnostic criteria and define clinically relevant subsets and biomarkers. She has a special interest in investigating characteristics of lung carcinomas defined by specific genomic alterations and neuroendocrine cancers. Dr. Rekhtman has published over 150 papers and multiple book chapters. She is the main editor and author of the book titled “Quick Reference Handbook for Surgical Pathologists”, the 2nd edition of which was published in 2019. Dr. Rekhtman has been an invited speaker at multiple national and international conferences, and serves as a co-director of the annual MSKCC/Massachusetts General Hospital course on thoracic pathology. She is a member of the NCI Steering Committee for Thoracic Malignancies and International Association for the Study of Lung Cancer pathology panel, among others. She is a member of Editorial Boards of several journals, and serves as an Associated Editor at Modern Pathology.
115

Novel Pathways and Targets in SCLC - Session 2

Presentations: 5 | 13:20 - 14:30 ET | 17:20 - 18:30 UTC
- 170
  
  Molecular Subtyping of Primary SCLC Tumors and Their Associations with Neuroendocrine and Therapeutic Markers
  
  13:20 - 13:32
  Speaker(s)
  
  Anish Thomas
  USA
  
  Anish Thomas is a clinical researcher and thoracic oncologist. The goals of his research program are: 1) to develop more effective therapies for patients with SCLC by targeting DNA replication, repair, and chromatin remodeling, and 2) genomic characterization of SCLCs to better understand the basis of treatment response and resistance. Work from his group has revealed replication stress as a transformative vulnerability of SCLCs characterized by high neuroendocrine differentiation, targetable by ATR inhibition (PMID: 33848478; PMID: 29252124), provided novel insights into the transcriptomic features that render low neuroendocrine SCLC more sensitive to immunotherapy (PMID: 34162872), and discovered a novel SCLC subset defined by the germline genotype and improved responses to DNA repair targeted drugs (PMID: 33504652).
- 171
  
  Molecular Subtyping of Primary SCLC Tumors and the Associations Between Molecular Subtypes and Therapeutic Biomarkers
  
  13:32 - 13:44
  Speaker(s)
  
  Haobin Chen
  USA
  
  Dr. Haobin Chen received his Ph.D. degree at New York University and completed his medical oncology fellowship at NCI. He has been a Physician Scientist Early Investigator at NCI since 2016.
- 172
  
  Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer
  
  13:44 - 13:56
  Speaker(s)
  
  Ralph Deberardinis
  USA
  
  Dr. Ralph DeBerardinis joined the faculty of UT Southwestern Medical Center in 2008 and joined the Children’s Medical Center Research Institute at UTSW (CRI) shortly after its founding in 2012. He is Chief of Pediatric Genetics and Metabolism at UTSW and Director of the Genetic and Metabolic Disease Program at CRI. Dr. DeBerardinis is a Howard Hughes Medical Institute Investigator and has received numerous awards including the William K. Bowes, Jr. Award in Medical Genetics, the National Cancer Institute’s Outstanding Investigator Award and The Academy of Medicine, Engineering & Science of Texas’s Edith and Peter O’Donnell Award in Medicine. He has been elected to the National Academy of Medicine and the Association of American Physicians. Dr. DeBerardinis’ laboratory studies the role of altered metabolic pathways in human diseases, including cancer and pediatric inborn errors of metabolism. The lab has pioneered the use of metabolomics and isotope tracing to characterize disease-associated metabolic states directly in patients, and to use disease-relevant model systems to explore how metabolic perturbations contributes to tissue dysfunction. Work from the DeBerardinis laboratory has produced new insights into disease mechanisms in numerous metabolic diseases, including by defining unexpected fuel preferences in human cancer and uncovering new metabolic vulnerabilities in cancer cells. Dr. DeBerardinis received a Bachelor of Science in Biology from St. Joseph’s University in Philadelphia before earning M.D. and Ph.D. degrees from the University of Pennsylvania’s School of Medicine. He completed his post-graduate clinical training at The Children’s Hospital of Philadelphia (CHOP) in Pediatrics, Medical Genetics and Clinical Biochemical Genetics. Before coming to UT Southwestern, he performed postdoctoral research at the Penn Cancer Center.
- 173
  
  Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes
  
  13:56 - 14:08
  Speaker(s)
  
  Silvia von Karstedt
  Germany
  
  Silvia von Karstedt, PhD, is a cell biologist who specializes in the investigation of regulated cell death in cancer. For her undergraduate and graduate studies, she joined the German Cancer Research Center (DKFZ) in Heidelberg, Germany, and Imperial College London, UK, respectively. Following a postdoctoral period at University College London with Henning Walczak and the Francis Crick Institute with Julian Downward, she set up her laboratory at the University of Cologne in September 2017. Her research interests include the function of different modes of cell death in KRAS-driven cancers and in the development and treatment of small cell lung cancer (SCLC). She has published in internationally renowned scientific journals as junior and senior author, received several poster and presentation prizes and is an active editorial board member and reviewer for nature publishing group journals.
- 174
  
  Panel Discussion with Q&A
  
  14:08 - 14:30
  Speaker(s)
  
  Haobin Chen
  USA
  
  Dr. Haobin Chen received his Ph.D. degree at New York University and completed his medical oncology fellowship at NCI. He has been a Physician Scientist Early Investigator at NCI since 2016.
  
  Ralph Deberardinis
  USA
  
  Dr. Ralph DeBerardinis joined the faculty of UT Southwestern Medical Center in 2008 and joined the Children’s Medical Center Research Institute at UTSW (CRI) shortly after its founding in 2012. He is Chief of Pediatric Genetics and Metabolism at UTSW and Director of the Genetic and Metabolic Disease Program at CRI. Dr. DeBerardinis is a Howard Hughes Medical Institute Investigator and has received numerous awards including the William K. Bowes, Jr. Award in Medical Genetics, the National Cancer Institute’s Outstanding Investigator Award and The Academy of Medicine, Engineering & Science of Texas’s Edith and Peter O’Donnell Award in Medicine. He has been elected to the National Academy of Medicine and the Association of American Physicians. Dr. DeBerardinis’ laboratory studies the role of altered metabolic pathways in human diseases, including cancer and pediatric inborn errors of metabolism. The lab has pioneered the use of metabolomics and isotope tracing to characterize disease-associated metabolic states directly in patients, and to use disease-relevant model systems to explore how metabolic perturbations contributes to tissue dysfunction. Work from the DeBerardinis laboratory has produced new insights into disease mechanisms in numerous metabolic diseases, including by defining unexpected fuel preferences in human cancer and uncovering new metabolic vulnerabilities in cancer cells. Dr. DeBerardinis received a Bachelor of Science in Biology from St. Joseph’s University in Philadelphia before earning M.D. and Ph.D. degrees from the University of Pennsylvania’s School of Medicine. He completed his post-graduate clinical training at The Children’s Hospital of Philadelphia (CHOP) in Pediatrics, Medical Genetics and Clinical Biochemical Genetics. Before coming to UT Southwestern, he performed postdoctoral research at the Penn Cancer Center.
  
  JT Poirier
  USA
  
  My lab focuses on the development of new treatment paradigms for lung cancer using three primary tools: genetic, epigenetic, and transcriptomic analyses; functional genomics using CRISPR-Cas9; and, high-fidelity patient-derived models of lung cancer. In addition to my primary research focus, I direct the Perlmutter Cancer Center Preclinical Therapeutics Program, which acquires viable human tumor cells from the clinic for the development of cancer models and tests experimental cancer therapeutics in the preclinical setting.
  
  Anish Thomas
  USA
  
  Anish Thomas is a clinical researcher and thoracic oncologist. The goals of his research program are: 1) to develop more effective therapies for patients with SCLC by targeting DNA replication, repair, and chromatin remodeling, and 2) genomic characterization of SCLCs to better understand the basis of treatment response and resistance. Work from his group has revealed replication stress as a transformative vulnerability of SCLCs characterized by high neuroendocrine differentiation, targetable by ATR inhibition (PMID: 33848478; PMID: 29252124), provided novel insights into the transcriptomic features that render low neuroendocrine SCLC more sensitive to immunotherapy (PMID: 34162872), and discovered a novel SCLC subset defined by the germline genotype and improved responses to DNA repair targeted drugs (PMID: 33504652).
  
  Silvia von Karstedt
  Germany
  
  Silvia von Karstedt, PhD, is a cell biologist who specializes in the investigation of regulated cell death in cancer. For her undergraduate and graduate studies, she joined the German Cancer Research Center (DKFZ) in Heidelberg, Germany, and Imperial College London, UK, respectively. Following a postdoctoral period at University College London with Henning Walczak and the Francis Crick Institute with Julian Downward, she set up her laboratory at the University of Cologne in September 2017. Her research interests include the function of different modes of cell death in KRAS-driven cancers and in the development and treatment of small cell lung cancer (SCLC). She has published in internationally renowned scientific journals as junior and senior author, received several poster and presentation prizes and is an active editorial board member and reviewer for nature publishing group journals.
116

Mouse Models in SCLC (Xenografts and GEMMs)

Presentations: 5 | 14:30 - 15:40 ET | 18:30 - 19:40 UTC
- 175
  
  PBRM1: A Novel Tumor Suppressor in Small Cell Lung Cancer
  
  14:30 - 14:42
  Speaker(s)
  
  Arnaud Augert
  USA
  
  My research program is dedicated to the study of small cell lung cancer (SCLC), a highly aggressive and lethal neuroendocrine tumor type characterized by rapid growth and widespread metastasis. Using cell biology, mouse genetics and cutting-edge molecular biology approaches, my laboratory will dissect the genetic and epigenetic mechanisms underlying small cell lung cancer initiation, progression, and response to therapies.
- 176
  
  Translesion DNA Synthesis Mediates Acquired Resistance to Olaparib plus Temozolomide in SCLC
  
  14:42 - 14:54
  Speaker(s)
  
  Benjamin Drapkin
  USA
  
  I am a medical oncologist at UT Southwestern specializing in the care of lung cancer patients, with a focus on small cell lung cancer (SCLC). My laboratory, located in the Hamon Center for Therapeutic Oncology, focuses on translational research in SCLC and other aggressive neuroendocrine tumors. We leverage a large panel of patient-derived xenograft (PDX) models that closely recapitulate the clinical features of their corresponding patients to discover new targets and develop new therapies for this deadly disease. Our two current areas of focus are: (1) strategies to overcome or circumvent chemotherapy cross-resistance, which renders relapsed SCLC refractory to further care, and (2) elucidation of the mechanism by which lineage transdifferentiation between lung adenocarcinoma and SCLC occurs.
  
  Marcello Stanzione
  USA
  
  Dr. Marcello Stanzione is a Postdoctoral Fellow at Massachusetts General Hospital – Cancer Center working in the laboratory of Dr. Nick Dyson. His research interests are focused on molecular mechanisms of acquired resistance to chemotherapy and DNA damage response pathways in cancer cells. He is studying the cellular responses to DNA damage induced by the chemotherapy and comparing damage induction, repair and tolerance in mouse xenograft models derived from Small Cell Lung Cancer patients before and after relapse. During his PhD at Max Planck Institute of Molecular Cell Biology and Genetics, Dresden Germany, Dr. Stanzione discovered the function and the spatiotemporal regulation of a novel protein essential for meiotic homologous recombination and crossover formation in mammals.
- 177
  
  Characterizing Chemoradiation Resistance in Small Cell Lung Cancer
  
  14:54 - 15:06
  Speaker(s)
  
  Luigi Marchionni
  USA
  
  Luigi Marchionni, M.D., Ph.D. is Associate Professor and vice-Chair for Computational and Systems Pathology at Weill Cornell Medicine. He has extensive experience in the analysis and interpretation of multi-omics and imaging data. Dr. Marchionni’s current research focuses on knowledge integration across different “omics” and imaging data types, the development of novel prediction algorithms for cancer prognostication and therapy selection, and the integration of “omics-based” predictors into current cancer patients clinical management. Dr. Marchionni works in close collaboration with “wet lab” researchers, to uncovering genetic contributions to interesting cancer phenotypes. To this end, in the past 10 years, Dr. Marchionni has worked closely with Drs. Hann and Tran to decipher the mechanisms underlying chemo-radiation resistance in small cell lung cancer through the integration of genome-wide data from patient derived xenografts.
- 178
  
  Modeling Oncogenic & Histologic Transformation in the Lung
  
  15:06 - 15:18
  Speaker(s)
  
  Eric Gardner
  USA
  
  Eric received his PharmD from the University of Pittsburgh School of Pharmacy then went on to receive his PhD from the Johns Hopkins University School of Medicine under the mentorship of physician-scientist Charlie Rudin. His thesis work focused on using patient-derived xenograft (PDX) models of small cell lung cancer to study mechanisms of acquired resistance to chemotherapy. He joined Harold Varmus's group for his postdoctoral work in 2018 and has been developing mouse models of oncogenic and histologic transformation in lung cancer. Eric is a Kenneth G. and Elaine A. Langone Fellow of the Damon Runyon Cancer Research Foundation and lives on the Upper East Side of Manhattan in NYC.
- 179
  
  Panel Discussion with Q&A
  
  15:18 - 15:40
  Speaker(s)
  
  Arnaud Augert
  USA
  
  My research program is dedicated to the study of small cell lung cancer (SCLC), a highly aggressive and lethal neuroendocrine tumor type characterized by rapid growth and widespread metastasis. Using cell biology, mouse genetics and cutting-edge molecular biology approaches, my laboratory will dissect the genetic and epigenetic mechanisms underlying small cell lung cancer initiation, progression, and response to therapies.
  
  Benjamin Drapkin
  USA
  
  I am a medical oncologist at UT Southwestern specializing in the care of lung cancer patients, with a focus on small cell lung cancer (SCLC). My laboratory, located in the Hamon Center for Therapeutic Oncology, focuses on translational research in SCLC and other aggressive neuroendocrine tumors. We leverage a large panel of patient-derived xenograft (PDX) models that closely recapitulate the clinical features of their corresponding patients to discover new targets and develop new therapies for this deadly disease. Our two current areas of focus are: (1) strategies to overcome or circumvent chemotherapy cross-resistance, which renders relapsed SCLC refractory to further care, and (2) elucidation of the mechanism by which lineage transdifferentiation between lung adenocarcinoma and SCLC occurs.
  
  Eric Gardner
  USA
  
  Eric received his PharmD from the University of Pittsburgh School of Pharmacy then went on to receive his PhD from the Johns Hopkins University School of Medicine under the mentorship of physician-scientist Charlie Rudin. His thesis work focused on using patient-derived xenograft (PDX) models of small cell lung cancer to study mechanisms of acquired resistance to chemotherapy. He joined Harold Varmus's group for his postdoctoral work in 2018 and has been developing mouse models of oncogenic and histologic transformation in lung cancer. Eric is a Kenneth G. and Elaine A. Langone Fellow of the Damon Runyon Cancer Research Foundation and lives on the Upper East Side of Manhattan in NYC.
  
  Luigi Marchionni
  USA
  
  Luigi Marchionni, M.D., Ph.D. is Associate Professor and vice-Chair for Computational and Systems Pathology at Weill Cornell Medicine. He has extensive experience in the analysis and interpretation of multi-omics and imaging data. Dr. Marchionni’s current research focuses on knowledge integration across different “omics” and imaging data types, the development of novel prediction algorithms for cancer prognostication and therapy selection, and the integration of “omics-based” predictors into current cancer patients clinical management. Dr. Marchionni works in close collaboration with “wet lab” researchers, to uncovering genetic contributions to interesting cancer phenotypes. To this end, in the past 10 years, Dr. Marchionni has worked closely with Drs. Hann and Tran to decipher the mechanisms underlying chemo-radiation resistance in small cell lung cancer through the integration of genome-wide data from patient derived xenografts.
  
  Roman Thomas
  Germany
  
  Marcello Stanzione
  USA
  
  Dr. Marcello Stanzione is a Postdoctoral Fellow at Massachusetts General Hospital – Cancer Center working in the laboratory of Dr. Nick Dyson. His research interests are focused on molecular mechanisms of acquired resistance to chemotherapy and DNA damage response pathways in cancer cells. He is studying the cellular responses to DNA damage induced by the chemotherapy and comparing damage induction, repair and tolerance in mouse xenograft models derived from Small Cell Lung Cancer patients before and after relapse. During his PhD at Max Planck Institute of Molecular Cell Biology and Genetics, Dresden Germany, Dr. Stanzione discovered the function and the spatiotemporal regulation of a novel protein essential for meiotic homologous recombination and crossover formation in mammals.
117

Immunotherapy Approaches in SCLC

Presentations: 5 | 15:40 - 16:50 ET | 19:40 - 20:50 UTC
- 180
  
  EZH2 and Plasticity of the Immune Response in SCLC
  
  15:40 - 15:52
  Speaker(s)
  
  David Barbie
  USA
  
  Dr. Barbie is a Thoracic Medical Oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. He is also Associate Director of the Belfer Center for Applied Cancer Science, as well as an Associate Member of the Broad Institute. Dr. Barbie earned his undergraduate degree at Harvard College and M.D. degree at Harvard Medical School, and was a Howard Hughes Medical Investigator Program Medical Student Research Fellow in Dr. Edward Harlow’s laboratory at the MGH Cancer Center. He then completed an MGH internal medicine resident and chief medical residency, a Dana-Farber Partners Oncology fellowship, and performed his post-doctoral work in Dr. William Hahn’s laboratory at DFCI and the Broad Institute. Currently he is principal investigator of his own laboratory at DFCI while also seeing patients in the Lowe Center for Thoracic Oncology. Dr. Barbie’s research has had a strong translational focus, studying the role of innate immunity in lung cancer. His early collaborations with Gilead Sciences led to the first TBK1 inhibitor trials using a repurposed multitargeted JAK inhibitor. He was principal investigator of a multicenter lung cancer clinical trial using this first-generation drug and his work also led to similar studies in colorectal and pancreatic cancer. Currently his laboratory is developing ways to co-opt TBK1 signaling to drive an antiviral response that can boost the impact of cancer immunotherapies. As a fellow he was the recipient of an ASCO Young Investigator award and NIH K08 grant. Since starting his laboratory he has also received an ASCI Young Physician Scientist Award and was elected as an ASCI Member in 2019. Currently he is a principal or co-principal investigator on multiple NIH grants including an R01, P01, and 2 U01 grants. He has also received significant funding from the V Foundation, SU2C, the Mark Foundation, the Ludwig Center, and the Parker Institute for Cancer Immunotherapy.
- 181
  
  Harnessing the Innate Immune System to Treat SCLC
  
  15:52 - 16:04
  Speaker(s)
  
  Kate Sutherland
  Australia
  
  A/Prof Kate Sutherland is a Laboratory Head at The Walter and Eliza Hall Institute of Medical Research (WEHI), developing state-of-the-art preclinical models of lung cancer. Kate completed her PhD in 2005 under the supervision of Profs Jane Visvader and Geoffrey Lindeman at WEHI. Upon completion of her studies, she moved to The Netherlands Cancer Institute in Amsterdam, where she undertook Postdoctoral studies in the laboratory of Prof Anton Berns. During this time Kate performed innovative studies that advanced the lung cancer field, by identifying the cell-of-origin of the two main subtypes of lung cancer. In 2013, Kate returned to WEHI to start her own laboratory dedicated to understanding tumour heterogeneity in lung cancer. In this time, she has developed new approaches and technologies to study lung cancer, leading to seminal findings on genetic drivers, the immune microenvironment and the role of the metabolome in these aggressive cancers. Kate has been the recipient of funding from Worldwide Cancer Research (UK), NHMRC and the Victorian Cancer Agency to support her work in designing precision medicine approaches for lung cancer patients. Her work has been published in high-impact journals including Cancer Cell, Cell Metabolism, PNAS and Journal of Thoracic Oncology. She serves on national and international committees (Lung Foundation Australia, Cancer Council of Victoria and the IASLC World Conference on Lung Cancer 2021). Kate passionately advocates for women in science, educating the next generation of research scientists and the value of fundamental lung cancer research in improving the treatment of patients.
- 182
  
  CDKs as Targets in Small Cell Lung Cancer
  
  16:04 - 16:16
  Speaker(s)
  
  Kwok-Kin Wong
  USA
- 183
  
  Examining Predictors of Response to Immune Checkpoint Blockade in Relapsed SCLC
  
  16:28 - 16:40
  Speaker(s)
  
  Nitin Roper
  USA
  
  After completing his undergraduate work at Brown University, Dr. Roper received his M.D. at the University of Connecticut School of Medicine. He completed an internship and residency in internal medicine at Mount Sinai Hospital in New York City. He subsequently obtained a Master’s in Clinical Research Methods from Columbia University, Mailman School of Public Health and was an Instructor in Medicine at Weill Cornell Medical College. He completed medical oncology training through the NHLBI-NCI Hematology Oncology Fellowship program and is board certified in Medical Oncology. Dr. Roper joined the Developmental Therapeutics Branch as a Physician-Scientist Early Investigator in 2019. Dr. Roper's laboratory is focused on small cell lung cancer and other neuroendocrine tumors. His goals are to 1) decipher the biologic mechanisms of SCLC and other neuroendocrine tumors that may, in turn, predict response or lack of response to immune checkpoint inhibition; 2) elucidate epigenetic mechanisms which may drive recurrent, treatment refractory SCLC and other neuroendocrine tumors; and 3) establish pre-clinical, patient-derived organoid models of rare neuroendocrine tumors.
- 184
  
  Panel Discussion with Q&A
  
  16:40 - 16:50
  Speaker(s)
  
  David Barbie
  USA
  
  Dr. Barbie is a Thoracic Medical Oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. He is also Associate Director of the Belfer Center for Applied Cancer Science, as well as an Associate Member of the Broad Institute. Dr. Barbie earned his undergraduate degree at Harvard College and M.D. degree at Harvard Medical School, and was a Howard Hughes Medical Investigator Program Medical Student Research Fellow in Dr. Edward Harlow’s laboratory at the MGH Cancer Center. He then completed an MGH internal medicine resident and chief medical residency, a Dana-Farber Partners Oncology fellowship, and performed his post-doctoral work in Dr. William Hahn’s laboratory at DFCI and the Broad Institute. Currently he is principal investigator of his own laboratory at DFCI while also seeing patients in the Lowe Center for Thoracic Oncology. Dr. Barbie’s research has had a strong translational focus, studying the role of innate immunity in lung cancer. His early collaborations with Gilead Sciences led to the first TBK1 inhibitor trials using a repurposed multitargeted JAK inhibitor. He was principal investigator of a multicenter lung cancer clinical trial using this first-generation drug and his work also led to similar studies in colorectal and pancreatic cancer. Currently his laboratory is developing ways to co-opt TBK1 signaling to drive an antiviral response that can boost the impact of cancer immunotherapies. As a fellow he was the recipient of an ASCO Young Investigator award and NIH K08 grant. Since starting his laboratory he has also received an ASCI Young Physician Scientist Award and was elected as an ASCI Member in 2019. Currently he is a principal or co-principal investigator on multiple NIH grants including an R01, P01, and 2 U01 grants. He has also received significant funding from the V Foundation, SU2C, the Mark Foundation, the Ludwig Center, and the Parker Institute for Cancer Immunotherapy.
  
  Ticiana Leal
  USA
  
  Ticiana A. Leal, MD, is an Associate Professor of Medicine in the Division of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin School of Medicine and Public Health. Dr. Leal earned her medical degree from the Federal University of Ceara, Brazil, and completed her residency at University of Chicago Hospitals. She completed her fellowship at University of Wisconsin Hospital and Clinics and the University of Illinois. Dr. Leal is board certified in medical oncology and palliative care medicine. She is a medical oncologist specializing in thoracic malignancies. She is a member of the NCCN NSCLC and mesothelioma/thymic malignancies panels. Her academic appointments include Thoracic Oncology Program Director, and Co-Chair of the Big Ten CRC Thoracic Clinical Trial Working Group. She is a member of the ECOG/ACRIN Thoracic Committee, NRG Oncology Medical Oncology Committee, and member of the IASLC LATAM Latin American Working Group, among many others. She has authored or coauthored numerous peer-reviewed original research articles, book chapters, and posters.
  
  Nitin Roper
  USA
  
  After completing his undergraduate work at Brown University, Dr. Roper received his M.D. at the University of Connecticut School of Medicine. He completed an internship and residency in internal medicine at Mount Sinai Hospital in New York City. He subsequently obtained a Master’s in Clinical Research Methods from Columbia University, Mailman School of Public Health and was an Instructor in Medicine at Weill Cornell Medical College. He completed medical oncology training through the NHLBI-NCI Hematology Oncology Fellowship program and is board certified in Medical Oncology. Dr. Roper joined the Developmental Therapeutics Branch as a Physician-Scientist Early Investigator in 2019. Dr. Roper's laboratory is focused on small cell lung cancer and other neuroendocrine tumors. His goals are to 1) decipher the biologic mechanisms of SCLC and other neuroendocrine tumors that may, in turn, predict response or lack of response to immune checkpoint inhibition; 2) elucidate epigenetic mechanisms which may drive recurrent, treatment refractory SCLC and other neuroendocrine tumors; and 3) establish pre-clinical, patient-derived organoid models of rare neuroendocrine tumors.
  
  Kate Sutherland
  Australia
  
  A/Prof Kate Sutherland is a Laboratory Head at The Walter and Eliza Hall Institute of Medical Research (WEHI), developing state-of-the-art preclinical models of lung cancer. Kate completed her PhD in 2005 under the supervision of Profs Jane Visvader and Geoffrey Lindeman at WEHI. Upon completion of her studies, she moved to The Netherlands Cancer Institute in Amsterdam, where she undertook Postdoctoral studies in the laboratory of Prof Anton Berns. During this time Kate performed innovative studies that advanced the lung cancer field, by identifying the cell-of-origin of the two main subtypes of lung cancer. In 2013, Kate returned to WEHI to start her own laboratory dedicated to understanding tumour heterogeneity in lung cancer. In this time, she has developed new approaches and technologies to study lung cancer, leading to seminal findings on genetic drivers, the immune microenvironment and the role of the metabolome in these aggressive cancers. Kate has been the recipient of funding from Worldwide Cancer Research (UK), NHMRC and the Victorian Cancer Agency to support her work in designing precision medicine approaches for lung cancer patients. Her work has been published in high-impact journals including Cancer Cell, Cell Metabolism, PNAS and Journal of Thoracic Oncology. She serves on national and international committees (Lung Foundation Australia, Cancer Council of Victoria and the IASLC World Conference on Lung Cancer 2021). Kate passionately advocates for women in science, educating the next generation of research scientists and the value of fundamental lung cancer research in improving the treatment of patients.
  
  Kwok-Kin Wong
  USA
118

Day 2 Closing

Presentations: 1 | 16:50 - 17:00 ET | 20:50 - 21:00 UTC
- 185
  
  Closing
  
  16:50 - 17:00
  Speaker(s)
  
  Charlie Rudin
  USA
  
  Dr. Rudin is a board-certified medical oncologist specializing in the care of patients with lung cancer. In addition to serving as Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, He co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee. He directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. They are interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
  
  Triparna Sen
  USA
  
  Dr. Triparna Sen, Ph.D., is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA. She has a broad background in translational oncology research, with a special interest in thoracic malignancies. Her research aims to understand changes in cancer cells at the molecular level that contribute to their growth, metastasis, and drug resistance. She then uses this knowledge to develop improved therapeutic strategies for clinically relevant molecular subsets of lung cancer. Dr. Sen has received independent grant funding from the Department of Defense (DoD) Lung Cancer Research Program, the National Institute of Health (NIH/NCI), the Lung Cancer Research Foundation, and The International Association for the Study of Lung Cancer (IASLC). She is the author of several peer-reviewed scientific manuscripts, and she is an active member of the IASLC, and the American Association for Cancer Research (AACR). She is also the co-director of the MSKCC lung cancer patient-derived xenograft (PDX) program, a platform that has developed over 300 preclinical models. The PDX program is a resource widely used for conducting co-clinical trials, identifying therapies and biomarkers by investigators worldwide. She has received several awards for her contribution to lung cancer research, including the 40 under 40 in Cancer award, AAAS Martin and Rose Wachtel Cancer Research Award, AACR Women in Cancer Research scholar award, and AACR Scholar-in-training Jeffrey Lee Cousins fellowship and Immuno-Oncology-Young Investigator award. She is actively involved in outreach activities, mentoring and a passionate advocate of equal opportunity for women in STEM fields. She has served as the two-time president of the Association for Women in Science Gulf Coast Houston Chapter and currently on the leadership board of 500 Women Scientists NYC pod.
121

Industry Sponsored Symposium By Jazz Pharmaceuticals: Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

Presentations: 1 | 17:05 - 18:20 ET | 21:05 - 22:20 UTC
- 186
  
  Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)
  
  17:05 - 18:20
  Speaker(s)
  
  Yuanbin Chen
  USA
  
  Yuanbin Chen, MD, PhD, MS, is Director of Thoracic Oncology and Melanoma Research and Vice President for Phase II/III Clinical Research at Cancer & Hematology Centers of Western Michigan in Grand Rapids, Michigan. In addition, he is Clinical Assistant Professor at Michigan State University College of Medicine in East Lansing. His primary clinical interests are thoracic oncology, melanoma, non-small cell lung cancer, and small cell lung cancer. Dr Chen earned his medical degree and master’s degree in pharmacology from Sun Yat-Sen University of Medical Sciences in Guangzhou, China, and his doctorate in molecular biology from Loyola University Chicago Medical Center in Maywood, Illinois. He completed his residency in internal medicine at Montefiore Medical Center, New York Medical College in Bronx, New York, and his fellowship in medical oncology at the National Institutes of Health/National Cancer Institute in Bethesda, Maryland. Dr Chen is a member of the American Society of Clinical Oncology, the American Society for Cancer Research and the International Association for the Study of Lung Cancer.

1635602400000

Benjamin Lok

Canada

IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer - Day 2

To collect your Attendance Certificate please email [email protected].

Benjamin Lok

Canada

Dr. Benjamin Lok is a Clinician-Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Radiation Oncology, Medical Biophysics, and the Institute of Medical Science, at the University of Toronto. He received his MD from New York University School of Medicine in 2012 followed by clinical residency with laboratory research training at Memorial Sloan Kettering Cancer Center. Since joining Princess Margaret in 2017, Dr. Lok has served as Staff Radiation Oncologist within the Lung Site Group. He leads a CIHR and NIH funded laboratory program with a mission to improve outcomes for lung cancer patients by understanding mechanisms of resistance and developing novel therapeutic strategies, particularly those related to DNA repair.

Opening Ceremony and Keynote

Chairs' Welcome Address

IASLC President Welcome

IASLC Membership: Why We Should All Be IASLC Members

Remembrance for Pierre Massion

Keynote: Lessons from SCLC CDX Models

Keynote Discussion with Q+A

Single Cell Analysis in SCLC

Signatures of Plasticity, Metastasis and Immunosuppression in a Single-cell Atlas of Human Small Cell Lung Cancer

Plasticity of SCLC Subtypes: Lessons from GEMMs

Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity

Single Cell Mass Cytometry and SCLC Models

Panel Discussion with Q&A

Omics in SCLC

Deciphering Tumor Evolution in Small Cell Lung Cancer​

Determination of Functional Impacts of Recurrent SCLC Mutations

Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer

Multi-omic Analysis of Lung Tumors Defines Pathways Involved in Lineage Plasticity

Panel Discussion with Q&A

Biomarkers/ Liquid Biopsy/ Metastasis in SCLC

Small Cell Lung Cancer Brain Metastases

Neddylation Inhibition as a Therapeutic Vulnerability in SCLC

Molecular Profiling and Phenotype Mapping of SCLC Using Patient-derived Organoids

SLFN11 in SCLC

Panel Discussion with Q&A

Novel Pathways and Targets in SCLC - Session 1

Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors

Radioimmunotherapy Targeting Delta-Like Ligand 3 in SCLC

Regulation of SCLC Neuroendocrine Plasticity by the RNA-Binding Protein ZFP36L1

Microenvironmental Interactions Between SCLC and Neurons

Panel Discussion with Q&A

Clinical Trials in SCLC

Phase I/II Study of Olaparib and Temozolomide in SCLC: Updated Analysis

Clinical Trials in SCLC Immunotherapy

Inflamed Subtype of SCLC and Clinical Implications

Panel Discussion with Q&A

Day 1 Closing

Day 1 Closing

Satellite CME Symposium By PeerView: Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next? (Watch this presentation at PeerView.com/SCLC2021-Virtual)

Early Career Session

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

XPO1 as a Target for Chemoresistance in SCLC

Profiling of the cfDNA Methylome for Detection and Subtyping of Small Cell Lung Cancers

Targeting CDK7 to Enhance Immunity in Small Cell Lung Cancer

To Be or Not to B7-H6: Advancing Immunotherapy in Small Cell Lung Cancer

Molecular Subtyping of SCLC in Tumor Tissues and CTCs

Panel Discussion with Q&A

Welcome and Keynote

Welcome

Keynote: Lessons from Mouse Models

Keynote Discussion with Q&A

Subtypes/ Biomarkers in SCLC

Histological Subtyping of SCLC

SCLC Subgroups and Their Potential Clinical Significance

Whole Genome Methylation Analysis of Extensive Stage SCLC Samples Reveals Distinct Subtype-Specific Patterns

SCLC Biomarkers for Lung Cancer Screening

Panel Discussion with Q&A

Novel Pathways and Targets in SCLC - Session 2

Molecular Subtyping of Primary SCLC Tumors and Their Associations with Neuroendocrine and Therapeutic Markers

Molecular Subtyping of Primary SCLC Tumors and the Associations Between Molecular Subtypes and Therapeutic Biomarkers

Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer

Ferroptosis Response Segregates Small Cell Lung Cancer (SCLC) Neuroendocrine Subtypes

Panel Discussion with Q&A

Mouse Models in SCLC (Xenografts and GEMMs)

PBRM1: A Novel Tumor Suppressor in Small Cell Lung Cancer

Translesion DNA Synthesis Mediates Acquired Resistance to Olaparib plus Temozolomide in SCLC

Characterizing Chemoradiation Resistance in Small Cell Lung Cancer

Modeling Oncogenic & Histologic Transformation in the Lung

Panel Discussion with Q&A

Immunotherapy Approaches in SCLC

EZH2 and Plasticity of the Immune Response in SCLC

Harnessing the Innate Immune System to Treat SCLC

CDKs as Targets in Small Cell Lung Cancer

Deciphering Tumor Evolution in Small Cell Lung Cancer